Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Eurogentec; NuGen Technologies; Orchid Cellmark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Eurogentec this week said that its Eurogentec North America subsidiary has received ISO 13485:2003 certification for the production and sale of oligonucleotides for the in vitro diagnostics market. The firm said that it is now the sole custom oligonucleotide contract manufacturing organization to be fully cGMP compliant and have ISO 13485 certified cleanroom sites in North America, Europe, and Asia.


NuGen Technologies has joined the Academy for Medical Development and Collaboration's Vendor Partnership Program, AMDeC announced this week. NuGen's sample preparation products for RNA and DNA analysis will be offered to AMDeC member institutions at a discounted price.


Orchid Cellmark this week said that it has reached an agreement with Accipiter Capital Management, under which Accipiter will nominate two individuals for election to Orchid Cellmark's board of directors. The nominees will serve as Class I directors for three-year terms ending in 2013. Orchid is scheduled to hold its annual shareholders' meeting on Nov. 9.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.